SP1 and kidney cancer: We speculate that continuous VEGF transcription, even in situations where HIF-1α (but not Sp1) is knocked out, could be the explanation for clinical studies where VEGF-targeting drugs have turned out to be effective in kidney cancer treatment as reported in [53].